Xiao-ning Gao
28 Fuxing Road
Beijing, 100853, China
Beijing, 100853, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications
Efficacy and Safety of Venetoclax-Based Chemotherapy Regimens for High-Risk Acute Myeloid Leukemia
Journal: Zhongguo shi yan xue ye xue za zhi
Published: June 02, 2026
Efficacy and Safety of Blinatumomab in Adult Patients with B-Cell Acute Lymphoblastic Leukemia
Journal: Zhongguo shi yan xue ye xue za zhi
Published: January 08, 2026
Efficacy and Safety of DCAG Regimen in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Journal: Zhongguo shi yan xue ye xue za zhi
Published: February 28, 2025
Outcomes of the transformation to diffuse large B-cell lymphoma in hodgkin lymphoma and indolent B-cell non-Hodgkin lymphoma: a population-based study.
Journal: Annals of hematology
Published: February 21, 2025
Updates from a single-center phase 2 study of PD-1 inhibitor combined with hypomethylating agent plus CAG regimen in patients with relapsed/refractory acute myeloid leukemia.
Journal: Frontiers in immunology
Published: November 24, 2024
WTAP-mediated m6A methylation of PHF19 facilitates cell cycle progression by remodeling the accessible chromatin landscape in t(8;21) AML.
Journal: Oncogene
Published: July 17, 2024
The Regulatory Effect of RNA m6 A Methylation Modification on KDM4B Gene Expression in t (8;21) AML Cells by MeRIP-qPCR
Journal: Zhongguo shi yan xue ye xue za zhi
Published: April 25, 2024
Anti-PD-1 combined with hypomethylating agent and CAG regimen bridging to allogeneic hematopoietic stem cell transplantation: a novel strategy for relapsed/refractory acute myeloid leukemia.
Journal: Frontiers in immunology
Published: March 29, 2024
Single-center phase 2 study of PD-1 inhibitor combined with DNA hypomethylation agent + CAG regimen in patients with relapsed/refractory acute myeloid leukemia.
Journal: Cancer immunology, immunotherapy : CII
Published: February 15, 2023
Hypomethylating agents (HMAs) show benefit in AML rather than in intermediate/high-risk MDS based on genetic mutations in epigenetic modification (EMMs): from a retrospective study.
Journal: Annals of hematology
Published: December 30, 2022
Study on Thalassemia in Han Population in Sanya of Hainan Province
Journal: Zhongguo shi yan xue ye xue za zhi
Published: February 06, 2022
Last Updated: 09/26/2026